Immuron gets go-ahead for finalisation of IMM-124E trials

By Trevor Hoey. Published at Jul 11, 2017, in ASX Biotechs

Shares in Immuron (ASX:IMC) traded nearly 7% higher on Monday morning after the company released positive interim results regarding the safety and efficacy of its ongoing IMM-124E Phase II study in non-alcoholic steatohepatitis (NASH).

Of course it should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

The objectives of the analysis were to establish the safety of the compound and to provide a preliminary read on efficacy signals. The trial enrolled 133 patients with the top line results expected in the fourth quarter of 2017.

These positive outcomes are extremely important given that they demonstrate that the IMM-124E compound is non-absorbable, safe and tolerable. Early biochemical improvements in liver enzymes were also noted, suggesting potential therapeutic benefits for the treatment of NASH.

The upshot of these developments has been a recommendation to continue the trial to completion given there is no concern for safety or futility.

Commenting on this development, IMC’s Chief Executive Thomas Liquard said, “NASH is increasingly viewed as a multifactorial disease whereby the approval of several chronic therapies with different MOAs and used in combination, will be needed to control its long-term effects”.

Liquard also noted that the results support the company’s belief that IMM-124E is a compound with a complex MOA that has the potential to have a beneficial impact in hard to treat fatty liver diseases.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why is Australia’s leading small cap publication

Founded seven years ago, is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise. provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more. is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!